AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2015
Nov 18, 2015
30583_dirs_2015-11-18_08059d4d-fb72-42d0-9739-45b306109c03.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2015-11-16
Reporting Person: GREY MICHAEL G (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-11-16 | Common Stock | M | 7500 | $38.59 | Acquired | 33750 | Direct |
| 2015-11-16 | Common Stock | S | 7500 | $104.2738 | Disposed | 26250 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-11-16 | Stock Option (right to buy) Common Stock | $38.59 | M | 7500 | Disposed | 2018-05-21 | Common Stock (7500) | Direct |
Footnotes
F1: Trade made pursuant to a 10b5-1 plan executed on August 14, 2015.
F2: The price in column 4 is a weighted average price. The price actually received ranged from $102.98 to $106.81. The reporting person shall provide to the issuer, and security holder of the issuer, or the SEC staff upon request, information regarding the number of shares sold at each price within the range
F3: Original option grant vests 6/48ths on November 22, 2008, and 1/48th on the 22nd day of every month thereafter.
F4: Reflects the number of stocks options that remain outstanding from this specific stock option grant following the reported transaction.